Free from Publisher

Erlotinib in the treatment of non-small cell lung cancer: current status and future developments

C Gridelli, P Maione, MA Bareschino… - Anticancer …, 2010 - ar.iiarjournals.org
Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …
被引用次数：48 相关文章

Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.

C Gridelli, P Maione, MA Bareschino… - Anticancer …, 2010 - europepmc.org
Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …
[PDF] iiarjournals.org

[PDF][PDF] Erlotinib in the Treatment of Non-small Cell Lung Cancer: Current Status and Future Developments

C GRIDELLI, P MAIONE… - ANTICANCER …, 2010 - ar.iiarjournals.org
Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …

[引用][C] Erlotinib in the Treatment of Non-small Cell Lung Cancer: Current Status and Future Developments

C GRIDELLI, P MAIONE, MA BARESCHINO… - Anticancer …, 2010 - pascal-francis.inist.fr
Erlotinib in the Treatment of Non-small Cell Lung Cancer: Current Status and Future
Developments CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

Erlotinib in the treatment of non-small cell lung cancer: current status and future developments

C Gridelli, P Maione, MA Bareschino… - Anticancer …, 2010 - pubmed.ncbi.nlm.nih.gov
Erlotinib is an orally small molecule inhibiting the tyrosine kinase activity of the epidermal
growth factor receptor (EGFR). Currently, erlotinib, at a standard oral daily dose of 150 mg, is …